Comparing the current results to its competitors, Teleflex Incorporated reported Revenue decrease in the 2 quarter 2026 year on year by -26.89 %, despite the revenue increase by the most of its competitors of 7.41 %, recorded in the same quarter.
Teleflex Incorporated's Comment on Competition and Industry Peers
The medical device industry is competitive, encompassing small start-ups and larger established companies with significant financial resources. The market involves extensive research and development and rapid technological advancements. The company competes based on clinical effectiveness, innovative features that improve patient outcomes, product reliability and performance, customer and sales support, and cost-efficiency.
May 1, 2025
Teleflex Reports Strong First Quarter, Eyes Growth for 2025 Amidst Thriving Medical Device IndustryBy WAYNE, Pa. May 1, 2025 In a landscape marked by rapid technological advancements and increased demand for innovative medical devices, Teleflex Incorporated (NYSE: TFX) has released its financial results for the first quarter of 2025, highlighting a promising trajectory that may signal robust growth for the remainder of the year.For the quarter ending March 30, 2025, Teleflex reported impressive earnings that reflect both resilience and strategic maneuvering in the competitive medical technology market. With 47.08 million shares outstanding, the company’s current share price stands at $137.05, illustr...
April 30, 2025
Breaking New Ground: Teleflex Enhances Hemostatic Device Indications and Expands Portfolio Wayne, Pa. April 30, 2025 In a significant step forward for medical technology and patient care, Teleflex Incorporated (NYSE: TFX), a prominent player in the global medical technology landscape, has announced the U.S. Food and Drug Administration (FDA) 510(k) clearance for expanded indications of its QuikClot Control+ Hemostatic Device. This pivotal development permits the use of the device for all grades of internal and external bleeding, widening its previous application scope from specific conditions such as class III and IV internal organ space bleeding to encompass even broader clinical scenarios. A Broader Sp...
July 31, 2024
By Author Name CSIMarket.com Teleflex, a global provider of medical technologies, is making significant strides in the realms of interventional cardiology and vascular access with a series of product launches that underscore their commitment to addressing unmet clinical needs. Ringer Perfusion Balloon Catheter: A New Horizon in Interventional CardiologyTeleflex has recently achieved a significant milestone with the U.S. Food and Drug Administration (FDA) 510(k) clearance of the Ringer Perfusion Balloon Catheter. This advanced catheter is specifically designed to provide interventionalists with innovative tools for enhanced patient care. The Ringer Perfusion Balloon Catheter is engineered to aid in precise...
July 29, 2024
Premier Members Gain Access to Enhanced Hemostatic Solutions at Exclusive Rates Teleflex Incorporated, a leading global provider of medical technologies, proudly announces the successful acquisition of hemostasis products agreements with Premier, Inc. Under these agreements, an array of advanced hemostatic dressings and devices are now available to Premier members at specially negotiated pricing, marking a significant advancement in hemostatic care accessibility within the healthcare sector.Premier, Inc. operates as a transformative healthcare improvement company, serving as a vital liaison to over 4,100 hospitals and health systems in the United States. Their collaborative model with healthcare providers ai...
May 7, 2024
Prostatic Urethral Lift (PUL) with the UroLift System has exhibited remarkable patient experience, according to new research findings presented at the 2024 American Urological Association Annual Meeting in San Antonio, TX. Teleflex Incorporated, a global leader in medical technologies, unveiled the outcomes from two groundbreaking head-to-head randomized controlled trials, highlighting the superiority of the UroLift System over Rezm and medical therapy as an early intervention for benign prostatic hyperplasia (BPH).BPH, a common condition affecting millions of men worldwide, is characterized by the non-cancerous enlargement of the prostate gland, leading to uncomfortable urinary symptoms. Traditionally, BPH ...
Becton Dickinson and Company operates a business model focused on developing and providing advanced medical technologies, including a diverse portfolio of medical devices and diagnostic products. Their strategy emphasizes innovation, quality, and strategic partnerships to enhance patient care and streamline healthcare processes across various settings.
ICU Medical Inc's business model focuses on the development, manufacture, and sale of innovative medical devices and solutions for critical care settings.
Ir med Inc's business model involves providing innovative medical technologies and solutions to the healthcare industry. The company focuses on developing and commercializing advanced medical devices that aim to improve patient outcomes and enhance overall healthcare management.
Livanova Plc is a global medical technology company that focuses on developing and delivering innovative solutions for patients with cardiovascular diseases and neuropsychiatric disorders. Through their diverse portfolio, they offer products and therapies that encompass surgical heart valves, cardiac rhythm management, and neuromodulation. Livanova adopts a patient-centric approach, collaborating with healthcare professionals to improve patient outcomes and enhance quality of life.
Lemaitre Vascular Inc is a medical device company specializing in the design, development, and distribution of innovative medical devices for the treatment of peripheral vascular disease. Their business model revolves around creating and manufacturing high-quality products that address specific needs in the field of vascular surgery. They leverage a combination of direct sales, distribution partnerships, and ongoing research and development efforts to effectively reach healthcare professionals and provide comprehensive solutions for patients.
Sources:
Teleflex Incorporated’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Teleflex Incorporated versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
